Skip header and navigation

Refine By

40 records – page 1 of 4.

Acute iliofemoral venous thrombosis in patients with atresia of the inferior vena cava can be treated successfully with catheter-directed thrombolysis.

https://arctichealth.org/en/permalink/ahliterature135647
Source
J Vasc Interv Radiol. 2011 Jun;22(6):801-5
Publication Type
Article
Date
Jun-2011
Author
Rikke Broholm
Maja Jørgensen
Sven Just
Leif P Jensen
Niels Bækgaard
Author Affiliation
Department of Vascular Surgery, Rigshospitalet and Gentofte Hospital, University of Copenhagen, Denmark. rbroholm@dadlnet.dk
Source
J Vasc Interv Radiol. 2011 Jun;22(6):801-5
Date
Jun-2011
Language
English
Publication Type
Article
Keywords
Acute Disease
Adolescent
Adult
Anticoagulants - administration & dosage
Catheterization, Peripheral
Denmark
Female
Femoral Vein - radiography
Fibrinolytic Agents - administration & dosage - adverse effects
Heparin - administration & dosage
Humans
Iliac Vein - radiography
Male
Middle Aged
Phlebography
Popliteal Vein
Retrospective Studies
Stockings, Compression
Thrombolytic Therapy - adverse effects
Time Factors
Tissue Plasminogen Activator - administration & dosage - adverse effects
Tomography, X-Ray Computed
Treatment Outcome
Vascular Malformations - complications - diagnosis
Vena Cava, Inferior - abnormalities - radiography - ultrasonography
Venous Thrombosis - complications - diagnosis - drug therapy
Warfarin - administration & dosage
Young Adult
Abstract
To assess the effectiveness and clinical outcomes of catheter-directed thrombolysis in patients with atresia of the inferior vena cava (IVC) and acute iliofemoral deep vein thrombosis (DVT).
From 2001 to 2009, 11 patients (median age, 32 y) with atresia of the IVC and acute iliofemoral DVT in 13 limbs were admitted for catheter-directed thrombolysis. Through a multiple-side hole catheter inserted in the popliteal vein, continuous pulse-spray infusion of tissue plasminogen activator and heparin was performed. Thrombolysis was terminated when all thrombus was resolved and venous outflow through the paravertebral collateral vessels was achieved. After thrombolysis, all patients received lifelong anticoagulation and compression stockings and were followed up at regular intervals.
Ultrasound or computed tomography revealed absence of the suprarenal segment of the IVC in two patients, and nine were diagnosed with absence of the infrarenal segment of the IVC. Median treatment time was 58 hours (range, 42-95 h). No deaths or serious complications occurred. Overall, complications were observed in four patients, one of whom required blood transfusion. Three patients were diagnosed with thrombophilia. Median follow-up was 37 months (range, 51 d to 96 mo). All patients had patent deep veins and one developed reflux in the popliteal fossa after 4 years. No thromboembolic recurrences were observed during follow-up.
Catheter-directed thrombolysis of patients with acute iliofemoral DVT and atresia of the IVC is a viable treatment option, as reasonable clinical outcomes can be obtained.
PubMed ID
21459610 View in PubMed
Less detail

Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis.

https://arctichealth.org/en/permalink/ahliterature153259
Source
Diabetes Care. 2009 Apr;32(4):617-22
Publication Type
Article
Date
Apr-2009
Author
Alexandre Y Poppe
Sumit R Majumdar
Thomas Jeerakathil
William Ghali
Alastair M Buchan
Michael D Hill
Author Affiliation
University of Calgary, Calgary, Alberta, Canada. alexander.poppe@albertahealthservices.ca
Source
Diabetes Care. 2009 Apr;32(4):617-22
Date
Apr-2009
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Anticoagulants - administration & dosage - therapeutic use
Canada
Cerebral Hemorrhage - complications - drug therapy - mortality
Cohort Studies
Diabetes Complications - drug therapy - mortality
Female
Humans
Hyperglycemia - complications
Infusions, Intravenous
Male
Middle Aged
Multicenter Studies as Topic
Multivariate Analysis
Prospective Studies
Regression Analysis
Risk factors
Stroke - complications - drug therapy - mortality
Tissue Plasminogen Activator - administration & dosage - therapeutic use
Treatment Outcome
Abstract
Admission hyperglycemia has been associated with worse outcomes in ischemic stroke. We hypothesized that hyperglycemia (glucose >8.0 mmol/l) in the hyperacute phase would be independently associated with increased mortality, symptomatic intracerebral hemorrhage (SICH), and poor functional status at 90 days in stroke patients treated with intravenous tissue plasminogen activator (IV-tPA).
Using data from the prospective, multicenter Canadian Alteplase for Stroke Effectiveness Study (CASES), the association between admission glucose >8.0 mmol/l and mortality, SICH, and poor functional status at 90 days (modified Rankin Scale >1) was examined. Similar analyses examining glucose as a continuous measure were conducted.
Of 1,098 patients, 296 (27%) had admission hyperglycemia, including 18% of those without diabetes and 70% of those with diabetes. After multivariable logistic regression, admission hyperglycemia was found to be independently associated with increased risk of death (adjusted risk ratio 1.5 [95% CI 1.2-1.9]), SICH (1.69 [0.95-3.00]), and a decreased probability of a favorable outcome at 90 days (0.7 [0.5-0.9]). An incremental risk of death and SICH and unfavorable 90-day outcomes was observed with increasing admission glucose. This observation held true for patients with and without diabetes.
In this cohort of IV-tPA-treated stroke patients, admission hyperglycemia was independently associated with increased risk of death, SICH, and poor functional status at 90 days. Treatment trials continue to be urgently needed to determine whether this is a modifiable risk factor for poor outcome.
Notes
Cites: Diabet Med. 2004 Apr;21(4):305-1015049930
Cites: Stroke. 2004 Aug;35(8):1886-9115192241
Cites: JAMA. 2004 Oct 20;292(15):1839-4415494581
Cites: Stroke. 1993 Jan;24(1):111-68418533
Cites: BMJ. 1997 May 3;314(7090):1303-69158464
Cites: Am J Crit Care. 2007 Jul;16(4):336-46; quiz 34717595363
Cites: Stroke. 2008 Feb;39(2):384-918096840
Cites: Circulation. 2008 Feb 26;117(8):1018-2718268145
Cites: Stroke. 2008 Jun;39(6):1751-818369171
Cites: Stroke. 2008 Oct;39(10):2749-5518703813
Cites: Lancet. 2000 May 13;355(9216):1670-410905241
Cites: Stroke. 2001 Oct;32(10):2426-3211588337
Cites: Neurology. 2001 Nov 13;57(9):1603-1011706099
Cites: Cerebrovasc Dis. 2002;13(2):89-9411867881
Cites: Neurology. 2002 Sep 10;59(5):669-7412221155
Cites: Stroke. 2003 May;34(5):1235-4112677014
Cites: Stroke. 2004 Aug;35(8):1903-715178819
Cites: Can J Neurol Sci. 1998 Aug;25(3):257-99706731
Cites: Stroke. 1999 Jan;30(1):34-99880385
Cites: CMAJ. 2005 May 10;172(10):1307-1215883405
Cites: Stroke. 2007 Jan;38(1):75-917122437
Cites: Lancet Neurol. 2007 May;6(5):397-40617434094
Cites: Brain. 2007 Jun;130(Pt 6):1626-3017525141
Cites: Circulation. 2007 May 22;115(20):e478-53417515473
PubMed ID
19131465 View in PubMed
Less detail

An angiographic assessment of alteplase: double-bolus and front-loaded infusion regimens in myocardial infarction. DouBLE Study Investigators. Double Bolus Lysis Efficacy.

https://arctichealth.org/en/permalink/ahliterature204254
Source
Am Heart J. 1998 Oct;136(4 Pt 1):741-8
Publication Type
Article
Date
Oct-1998
Author
S D Bleich
A A Adgey
S R McMechan
T W Love
Author Affiliation
Cardiology Associates of Jefferson, East Jefferson General Hospital, Metairie, LA 70006, USA.
Source
Am Heart J. 1998 Oct;136(4 Pt 1):741-8
Date
Oct-1998
Language
English
Publication Type
Article
Keywords
Aged
Canada
Coronary Angiography
Drug Administration Schedule
Female
Great Britain
Humans
Infusions, Intravenous
Injections, Intravenous
Male
Middle Aged
Myocardial Infarction - drug therapy - radiography
Plasminogen Activators - administration & dosage
Tissue Plasminogen Activator - administration & dosage
Treatment Outcome
United States
Abstract
This study was designed to investigate the efficacy of alteplase double-bolus dosing compared with the front-loaded 90-minute infusion regimen in patients with acute myocardial infarction. Recent pilot studies have suggested that bolus dosing may provide improved efficacy in establishing early, complete, and sustained patency of the infarct-related artery in the thrombolytic treatment of acute myocardial infarction.
In this multicenter, randomized, open-label trial, 461 patients with acute myocardial infarction received 100 mg alteplase as a front-loaded 90-minute infusion (15 mg bolus, then 50 mg over a 30-minute period, then 35 mg over a 60-minute period) or double bolus (two 50 mg bolus injections 30 minutes apart). All patients also received intravenous heparin and oral aspirin during and after alteplase treatment. The 90-minute angiographic patency rates were 74.5% in the double-bolus group and 81.4% in the infusion group (p = 0.08). Patency rates were also comparable for the two groups at 60 minutes (76.8% vs 77.5%) and 24 hours (95.5% vs 93.5%) after initiation of treatment. In-hospital mortality rates were 4.5% in the bolus group and 1.3% in the infusion group (p = 0.04); 30-day mortality rates were 4.5% and 1.7%, respectively (p = NS). The two-groups were comparable in frequency of all other adverse events.
Double-bolus alteplase administration produced reperfusion rates comparable to front-loaded infusion, but in-hospital and 30-day mortality rates were higher in the double-bolus group. These findings are in agreement with those of the COBALT megatrial, which also reported a trend to higher mortality rates with double-bolus dosing.
Notes
Comment In: Am Heart J. 1998 Oct;136(4 Pt 1):570-39778057
PubMed ID
9778080 View in PubMed
Less detail

Characteristics and outcome of ischemic stroke patients who are free of symptoms at 24 hours following thrombolysis.

https://arctichealth.org/en/permalink/ahliterature139771
Source
Cerebrovasc Dis. 2011;31(1):37-42
Publication Type
Article
Date
2011
Author
Daniel Strbian
Tiina Sairanen
Kirsi Rantanen
Katja Piironen
Sari Atula
Turgut Tatlisumak
Lauri Soinne
Author Affiliation
Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland.
Source
Cerebrovasc Dis. 2011;31(1):37-42
Date
2011
Language
English
Publication Type
Article
Keywords
Age Factors
Aged
Blood Glucose - analysis
Brain Ischemia - diagnosis - drug therapy - mortality
Disability Evaluation
Female
Fibrinolytic Agents - administration & dosage
Finland
Humans
Logistic Models
Male
Middle Aged
Odds Ratio
Patient Admission
Registries
Risk assessment
Risk factors
Severity of Illness Index
Stroke - diagnosis - drug therapy - mortality
Thrombolytic Therapy
Time Factors
Tissue Plasminogen Activator - administration & dosage
Treatment Outcome
Abstract
A part of ischemic stroke patients score 0 on the National Institutes of Health Stroke Scale (NIHSS) within 24 h following thrombolysis. Their clinical characteristics and long-term outcome are poorly studied. We report a single-center assessment of such patients.
The cohort comprises 874 consecutive patients from the Helsinki Stroke Thrombolysis Registry, out of whom 113 scored 0 on 24-hour NIHSS. We analyzed their baseline demographic, clinical and radiological characteristics and 3-month outcome (modified Rankin Scale, mRS). Associations between the study parameters were tested by multivariate analysis.
Patients with a 24-hour NIHSS score = 0 (n = 113) were younger than the rest of the population (n = 761; median: 65.6 vs. 71.5 years; p
PubMed ID
20980752 View in PubMed
Less detail

Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators.

https://arctichealth.org/en/permalink/ahliterature196692
Source
Eur Heart J. 2000 Dec;21(23):1944-53
Publication Type
Article
Date
Dec-2000
Author
E M Antman
C M Gibson
J A de Lemos
R P Giugliano
C H McCabe
P. Coussement
I. Menown
C A Nienaber
T C Rehders
M J Frey
R. Van der Wieken
D. Andresen
J. Scherer
K. Anderson
F. Van de Werf
E. Braunwald
Author Affiliation
Brigham and Women's Hospital, Boston, MA 02115, USA.
Source
Eur Heart J. 2000 Dec;21(23):1944-53
Date
Dec-2000
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Antibodies, Monoclonal - administration & dosage
Canada
Coronary Angiography
Drug Administration Schedule
Drug Therapy, Combination
Electrocardiography
Europe
Female
Heparin - administration & dosage
Humans
Immunoglobulin Fab Fragments - administration & dosage
Male
Middle Aged
Myocardial Infarction - drug therapy
Plasminogen Activators - administration & dosage
Platelet Aggregation Inhibitors - administration & dosage
Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors
Recombinant Proteins - administration & dosage
Thrombolytic Therapy
Tissue Plasminogen Activator - administration & dosage
Treatment Outcome
United States
Abstract
Aims Abciximab has previously been shown to enhance thrombolysis and improve myocardial perfusion when combined with reduced doses of alteplase. The purpose of the reteplase phase of TIMI 14 was to evaluate the effects of abciximab when used in combination with a reduced dose of reteplase for ST-elevation myocardial infarction. Methods and Results Patients (n=299) with ST-elevation myocardial infarction were treated with aspirin and randomized to a control arm with standard dose reteplase (10+10 U given 30 min apart) or abciximab (bolus of 0.25 mg. kg(-1)and 12-h infusion of 0.125 microg. kg(-1). min(-1)) in combination with reduced doses of reteplase (5+5 U or 10+5 U). Control patients received standard weight-adjusted heparin (bolus of 70 U. kg(-1); infusion of 15 U. kg(-1). h(-1)), while each of the combination arms with abciximab and reduced dose reteplase received either low dose heparin (bolus of 60 U. kg(-1); infusion of 7 U. kg(-1). h(-1)) or very low dose heparin (bolus of 30 U. kg(-1); infusion of 4 U. kg(-1). h(-1)). The rate of TIMI 3 flow at 90 min was 70% for patients treated with 10+10 U of reteplase alone (n=87), 73% for those treated with 5+5 U of reteplase with abciximab (n=88), and 77% for those treated with 10+5 U of reteplase with abciximab (n=75). Complete (>/=70%) ST resolution at 90 min was seen in 56% of patients receiving a reduced dose of reteplase in combination with abciximab compared with 48% of patients receiving reteplase alone. Conclusions Reduced doses of reteplase when administered in combination with abciximab were associated with higher TIMI 3 flow rates than reported previously for reduced doses of reteplase without abciximab and were at least as high as for full dose reteplase alone
Notes
Comment In: Eur Heart J. 2000 Dec;21(23):1913-611071795
PubMed ID
11071800 View in PubMed
Less detail

Coronary thrombolysis--clinical guidelines and public policy: results of an Ontario practitioner survey.

https://arctichealth.org/en/permalink/ahliterature229068
Source
CMAJ. 1990 May 15;142(10):1069-76
Publication Type
Article
Date
May-15-1990
Author
C D Naylor
A A Hollenberg
A M Ugnat
A. Basinski
Author Affiliation
Clinical Epidemiology Unit, Toronto Hospital, Ont.
Source
CMAJ. 1990 May 15;142(10):1069-76
Date
May-15-1990
Language
English
Publication Type
Article
Keywords
Attitude of Health Personnel
Cardiology
Fibrinolytic Agents - administration & dosage
Financing, Government
Health Policy
Humans
Internal Medicine
Myocardial Infarction - drug therapy
Ontario
Physicians
Questionnaires
Societies, Medical
Streptokinase - administration & dosage
Tissue Plasminogen Activator - administration & dosage
Abstract
The Ontario Medical Association (OMA) guidelines for intravenous thrombolysis in acute myocardial infarction were released in March 1988 and contributed to a government decision against special per-case funding to assist hospitals using tissue-type plasminogen activator (tPA). In October 1988, 1512 cardiologists, internists and physician-administrators who were OMA members were mailed a questionnaire seeking their views on the OMA guidelines and related issues. Of the 419 questionnaires (28%) that were returned, 392 contained usable responses. Among the respondents 268 (68%) had used thrombolytic drugs in the preceding 12 months; the mean number of cases was 10.6 (standard deviation 12.9). A strong or a mild preference for tPA over streptokinase was registered by 64% of the respondents; 28% had no preference. However, the self-reported ratio of actual streptokinase:tPA use was about 3:1, and 73% indicated that the government's funding policy had limited the availability of tPA in their hospital. The respondents were almost equally divided as to whether the policy should be changed. The guidelines were deemed helpful by 85% of the noncardiologists, as opposed to 52% of the cardiologists (p less than 0.005). OMA involvement in developing and circulating such guidelines was supported by 74% of the respondents and opposed by 18%; opposition was more likely to come from those who found the guidelines unhelpful (p less than 0.001). Support for involvement by the College of Physicians and Surgeons of Ontario was much weaker (supported by 32%, opposed by 62%). Overwhelming opposition to government involvement was evident.
Notes
Cites: Lancet. 1988 Sep 3;2(8610):525-302900919
Cites: Nature. 1988 Apr 14;332(6165):5773128738
Cites: CMAJ. 1989 Jun 1;140(11):1289-992497946
Cites: CMAJ. 1989 Nov 1;141(9):861-62804833
Cites: Lancet. 1985 Apr 13;1(8433):842-72858711
PubMed ID
2110859 View in PubMed
Less detail

Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke.

https://arctichealth.org/en/permalink/ahliterature166388
Source
Stroke. 2007 Jan;38(1):85-9
Publication Type
Article
Date
Jan-2007
Author
Lars Ehlers
Grethe Andersen
Lone Beltoft Clausen
Merete Bech
Mette Kjølby
Author Affiliation
HTA Unit, Aarhus University Hospital, Olof Palmes Allé 17, 8200 Aarhus N, Denmark. le@ag.aaa.dk
Source
Stroke. 2007 Jan;38(1):85-9
Date
Jan-2007
Language
English
Publication Type
Article
Keywords
Acute Disease
Brain Ischemia - diagnosis - drug therapy
Clinical Protocols - standards
Cost-Benefit Analysis
Decision Trees
Denmark
Fibrinolytic Agents - economics - therapeutic use
Health Care Costs
Humans
Infusions, Intravenous
Magnetic Resonance Imaging - economics - utilization
Markov Chains
Models, Econometric
Monte Carlo Method
Patient Selection
Predictive value of tests
Preoperative Care - standards
Quality-Adjusted Life Years
Stroke - diagnosis - drug therapy
Thrombolytic Therapy - economics
Time
Time Factors
Tissue Plasminogen Activator - administration & dosage - economics - therapeutic use
Treatment Outcome
Abstract
The aim of this study was to assess the costs and cost-effectiveness of intravenous thrombolysis treatment with alteplase (Actilyse) of acute ischemic stroke with 24-hour in-house neurology coverage and use of magnetic resonance imaging.
A health economic model was designed to calculate the marginal cost-effectiveness ratios for time spans of 1, 2, 3 and 30 years. Effect data were extracted from a meta-analysis of six large-scale randomized and placebo-controlled studies of thrombolytic therapy with alteplase. Cost data were extracted from thrombolysis treatment at Aarhus Hospital, Denmark, and from previously published literature.
The calculated cost-effectiveness ratio after the first year was $55,591 US per quality-adjusted life-year (base case). After the second year, computation of the cost-effectiveness ratio showed that thrombolysis was cost-effective. The long-term computations (30 years) showed that thrombolysis was a dominant strategy compared with conservative treatment given the model premises.
A high-quality thrombolysis treatment with 24-hour in-house neurology coverage and magnetic resonance imaging might not be cost-effective in the short term compared with conservative treatment. In the long term, there are potentially large-scale health economic cost savings.
PubMed ID
17122430 View in PubMed
Less detail

Determinants of early and long-term efficacy of catheter-directed thrombolysis in proximal deep vein thrombosis.

https://arctichealth.org/en/permalink/ahliterature118704
Source
J Vasc Interv Radiol. 2013 Jan;24(1):17-24; quiz 26
Publication Type
Article
Date
Jan-2013
Author
Ylva Haig
Tone Enden
Carl-Erik Slagsvold
Leiv Sandvik
Per Morten Sandset
Nils Einar Kløw
Author Affiliation
Department of Radiology, Oslo University Hospital, Oslo, Norway. iynhaig@medisin.uio.no
Source
J Vasc Interv Radiol. 2013 Jan;24(1):17-24; quiz 26
Date
Jan-2013
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Catheterization, Peripheral - statistics & numerical data
Female
Fibrinolytic Agents - administration & dosage
Humans
Incidence
Longitudinal Studies
Male
Middle Aged
Norway - epidemiology
Risk factors
Thrombolytic Therapy - statistics & numerical data
Tissue Plasminogen Activator - administration & dosage
Treatment Outcome
Venous Thrombosis - diagnosis - drug therapy - epidemiology
Young Adult
Abstract
Catheter-directed thrombolysis (CDT) for proximal deep vein thrombosis (DVT) effectively enhances clot removal and recently has been shown to reduce the development of postthrombotic syndrome (PTS). This study was performed to identify potential markers for early and long-term efficacy of CDT, adverse events, and their interrelationship.
Patients aged 18-75 years (mean, 54 y; 33 women) with first-time proximal DVT and symptoms up to 21 days were included in subanalyses in an open, multicenter, randomized, controlled trial. Early efficacy was assessed with a thrombus score based on daily venography. Six-month and 2-year follow-up included iliofemoral patency assessed with duplex ultrasound and air plethysmography, and PTS was assessed with the Villalta scale.
A mean clot resolution of 82%±25 was achieved in 92 patients. Successful lysis (ie,=50%) was obtained in 83 patients. Early efficacy was equal for femoral and iliofemoral thrombus and not related to thrombus load before CDT, symptom duration, or predisposing risk factors. Lower thrombus score at completion of CDT was associated with increased patency at 24 months (P = .040), and increased patency after 6 and 24 months was correlated with reduced development of PTS after 24 months (P
Notes
Comment In: J Vasc Interv Radiol. 2013 Jan;24(1):24-623273694
PubMed ID
23176966 View in PubMed
Less detail

[Documentation behind recommendations is missing].

https://arctichealth.org/en/permalink/ahliterature214916
Source
Lakartidningen. 1995 Jun 28;92(26-27):2651
Publication Type
Article
Date
Jun-28-1995

DWI-ASPECTS as a predictor of dramatic recovery after intravenous recombinant tissue plasminogen activator administration in patients with middle cerebral artery occlusion.

https://arctichealth.org/en/permalink/ahliterature118409
Source
Stroke. 2013 Feb;44(2):534-7
Publication Type
Article
Date
Feb-2013
Author
Junya Aoki
Kazumi Kimura
Kensaku Shibazaki
Yuki Sakamoto
Author Affiliation
Department of Stroke Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki City, Okayama 701-0192, Japan. aojyun@med.kawasaki-m.ac.jp
Source
Stroke. 2013 Feb;44(2):534-7
Date
Feb-2013
Language
English
Publication Type
Article
Keywords
Administration, Intravenous
Aged
Aged, 80 and over
Alberta - epidemiology
Diffusion Magnetic Resonance Imaging - methods
Female
Humans
Infarction, Middle Cerebral Artery - diagnosis - drug therapy
Male
Predictive value of tests
Prospective Studies
Recovery of Function - drug effects - physiology
Tissue Plasminogen Activator - administration & dosage
Tomography, X-Ray Computed - methods
Treatment Outcome
Abstract
In patients with middle cerebral artery trunk occlusion we investigated whether the diffusion-weighted imaging- the Alberta Stroke Program Early Computed Tomography Score (DWI-ASPECTS) predicts short-term neurological recovery after intravenous recombinant tissue plasminogen activator administration, and investigated how DWI-ASPECTS relates to clinical outcome.
Dramatic recovery was defined as a = 10-point reduction or a total National Institutes of Health Stroke Scale score of 0 to 1 at 24 hours and 7 days. Early recanalization was defined as recanalization within 1 hours after intravenous recombinant tissue plasminogen activator. Favorable outcome at 3 months was defined as a modified Rankin Scale score of 0 to 2.
Sixty-six patients (median age [interquartile], 79 [70-85] years, male; 34 [52%]) were enrolled. DWI-ASPECTS was 6 (5-9). Dramatic recovery was seen in 16 (24%) and 26 (39%) patients at 24 hours and on day 7, respectively. Early recanalization occurred in 22 (33%) patients. DWI-ASPECTS = 7 was an independent predictor of dramatic recovery at 24 hours (odds ratio, 100.85; 95% confidence interval, 4.29-2371.40; P=0.004) and 7 days (odds ratio, 14.15; 95% confidence interval, 2.21-90.48; P=0.005). Although the favorable outcome rate was not significantly different between patients with DWI-ASPECTS = 7 with and without early recanalization (60% versus 31%; P=0.228), it was statistically more frequent in patients with DWI-ASPECTS
PubMed ID
23212169 View in PubMed
Less detail

40 records – page 1 of 4.